Pacific Biosciences Of California (PACB) Liabilities and Shareholders Equity (2016 - 2025)
Pacific Biosciences Of California (PACB) has 16 years of Liabilities and Shareholders Equity data on record, last reported at $784.1 million in Q4 2025.
- For Q4 2025, Liabilities and Shareholders Equity fell 37.79% year-over-year to $784.1 million; the TTM value through Dec 2025 reached $3.3 billion, down 44.42%, while the annual FY2025 figure was $784.1 million, 37.79% down from the prior year.
- Liabilities and Shareholders Equity reached $784.1 million in Q4 2025 per PACB's latest filing, down from $803.2 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $2.0 billion in Q3 2021 and bottomed at $784.1 million in Q4 2025.
- Average Liabilities and Shareholders Equity over 5 years is $1.5 billion, with a median of $1.7 billion recorded in 2023.
- Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 577.33% in 2021, then tumbled 48.45% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.0 billion in 2021, then fell by 11.95% to $1.8 billion in 2022, then dropped by 1.19% to $1.7 billion in 2023, then fell by 27.81% to $1.3 billion in 2024, then crashed by 37.79% to $784.1 million in 2025.
- Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $784.1 million in Q4 2025, $803.2 million in Q3 2025, and $825.5 million in Q2 2025.